Literature DB >> 19224899

Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin.

Mahmoud A Pouladi1, Rona K Graham, Joanna M Karasinska, Yuanyun Xie, Rachelle Dar Santos, Asa Petersén, Michael R Hayden.   

Abstract

Huntington disease is a neurodegenerative disorder caused by an expanded CAG repeat in the Huntington disease gene. The symptomatic phase of the disease is defined by the onset of motor symptoms. However, psychiatric disturbances, including depression, are common features of Huntington disease and recent studies indicate that depression can occur long before the manifestation of motor symptoms. The aetiology of depression in Huntington disease is not fully understood and psychosocial factors such as the knowledge of carrying a mutation for an incurable disease or adverse social circumstances may contribute to its presentation. Due to the difficulties in discriminating between social and biological factors as contributors to depression in clinical Huntington disease, we chose to assess whether a model for Huntington disease not subject to environmental stressors, namely the YAC mouse model of Huntington disease, displays a depressive phenotype. Indeed, the YAC transgenic mice recapitulate the early depressive phenotype of Huntington disease as assessed by the Porsolt forced swim test as well as the sucrose intake test as a measure of anhedonia. The YAC model mirrors clinical Huntington disease in that there were no effects of CAG repeat length or disease duration on the depressive phenotype. The depressive phenotype was completely rescued in YAC transgenic animals expressing a variant of mutant huntingtin that is resistant to cleavage at amino acid 586 suggesting that therapies aimed towards inhibition of huntingtin cleavage are also likely to have beneficial effects on this aspect of the disease. In conclusion, our study provides strong support for a primary neurobiological basis for depression in Huntington disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224899     DOI: 10.1093/brain/awp006

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  56 in total

1.  Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Rα receptor.

Authors:  Xiaojun Wu; Hung Hsuchou; Abba J Kastin; Yi He; Reas S Khan; Kirsten P Stone; Michael S Cash; Weihong Pan
Journal:  Psychoneuroendocrinology       Date:  2010-08-17       Impact factor: 4.905

2.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound.

Authors:  Dagmar E Ehrnhoefer; Niels H Skotte; Jeanette Reinshagen; Xiaofan Qiu; Björn Windshügel; Priyadarshini Jaishankar; Safia Ladha; Olga Petina; Mehdi Khankischpur; Yen T N Nguyen; Nicholas S Caron; Adelia Razeto; Matthias Meyer Zu Rheda; Yu Deng; Khuong T Huynh; Ilka Wittig; Philip Gribbon; Adam R Renslo; Detlef Geffken; Sheraz Gul; Michael R Hayden
Journal:  Cell Chem Biol       Date:  2019-07-25       Impact factor: 8.116

4.  An optimized activity-based probe for the study of caspase-6 activation.

Authors:  Laura E Edgington; Bram J van Raam; Martijn Verdoes; Christoph Wierschem; Guy S Salvesen; Matthew Bogyo
Journal:  Chem Biol       Date:  2012-03-23

Review 5.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

6.  Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice.

Authors:  Valeria Uribe; Bibiana K Y Wong; Rona K Graham; Corey L Cusack; Niels H Skotte; Mahmoud A Pouladi; Yuanyun Xie; Konstantin Feinberg; Yimiao Ou; Yingbin Ouyang; Yu Deng; Sonia Franciosi; Nagat Bissada; Amanda Spreeuw; Weining Zhang; Dagmar E Ehrnhoefer; Kuljeet Vaid; Freda D Miller; Mohanish Deshmukh; David Howland; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-01-18       Impact factor: 6.150

Review 7.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

8.  HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Authors:  Dagmar E Ehrnhoefer; Amber L Southwell; Meenalochani Sivasubramanian; Xiaofan Qiu; Erika B Villanueva; Yuanyun Xie; Sabine Waltl; Lisa Anderson; Anita Fazeli; Lorenzo Casal; Boguslaw Felczak; Michelle Tsang; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

9.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07

10.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.